颞肌厚度对3-12岁儿童髓母细胞瘤患者的预后价值
这项回顾性多中心队列研究纳入303例髓母细胞瘤患者,术前MRI测量颞肌厚度(TMT),在3-12岁230例患者中分析其与预后的关系。训练队列确定TMT截断值6.115 mm,高于该值者PFS和OS显著更优,并在测试队列及两个独立验证队列中得到验证。
要点
- 3-12岁髓母细胞瘤患者术前MRI颞肌厚度与预后相关。
- TMT截断值6.115 mm可区分PFS和OS显著不同的两组。
- TMT或有助于风险分层和治疗规划,但需大样本前瞻性研究验证。
核心结论
- MRI测量的颞肌厚度是3-12岁髓母细胞瘤患者的潜在预后指标,可能有助于指导风险分层和治疗规划。
研究设计与样本
- 回顾性多中心队列研究,共纳入303例髓母细胞瘤患者,其中230例年龄3-12岁,术前颅脑MRI测量颞肌厚度,分为训练队列和测试队列。
主要发现
- TMT与年龄和体重指数呈正相关,与脑积水和转移的存在呈负相关。
- 训练队列确定TMT截断值6.115 mm,对PFS和OS均为显著阈值。
- 5年PFS率:低TMT组(38.0 ± 11.5)% vs 高TMT组(88.3 ± 3.2)%;5年OS率:(57.2 ± 8.7)% vs(96.5 ± 1.7)%。
- 多因素Cox回归显示高于截断值者PFS显著更优(HR = 0.165;95%CI:0.064-0.427;P < 0.001),OS亦显著更优(HR = 0.064;95%CI:0.020-0.207;P < 0.001)。
- 上述发现在测试队列和两个独立验证队列中得到验证。
关键数值与推荐
- TMT截断值6.115 mm用于区分3-12岁髓母细胞瘤患者的PFS和OS。
- 高于截断值者PFS的HR = 0.165(95%CI:0.064-0.427;P < 0.001),OS的HR = 0.064(95%CI:0.020-0.207;P < 0.001)。
临床怎么用
- 对3-12岁髓母细胞瘤患者,可考虑术前MRI测量TMT辅助预后评估和风险分层。
- TMT低于6.115 mm者预后较差,或需更密切随访和强化治疗规划。
局限性
- 本研究为回顾性设计。
- 临床适用性仍需大样本前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This retrospective, multicenter cohort study aimed to investigate the prognostic significance of temporal muscle thickness (TMT) in medulloblastoma (MB) patients. METHODS: Preoperative cranial MRI was used to measure TMT. Patients were divided into training and test cohorts. An optimal TMT cutoff for progression-free survival (PFS) and overall survival (OS) was established. RESULTS: Among the 303 enrolled MB patients, TMT was found to be associated with prognosis in the 230 patients aged 3-12 years. TMT demonstrated positive correlations with age and body mass index, while inverse associations were observed with the presence of hydrocephalus and metastasis. A TMT cutoff value of 6.115 mm was established in the training cohort, which served as a significant threshold for both PFS and OS. The 5-year PFS rates were (38.0 ± 11.5) % (low mean-TMT group) versus (88.3 ± 3.2) % (high mean-TMT group), and OS rates were (57.2 ± 8.7) % versus (96.5 ± 1.7) %, respectively. The multivariate Cox regression revealed significantly better PFS (hazard ratio (HR) = 0.165; 95% confidence interval (CI): 0.064-0.427; P < 0.001) and OS (HR = 0.064; 95% CI: 0.020-0.207; P < 0.001) in patients above versus below this cutoff. These findings were validated in test cohort and two independent validation cohorts. CONCLUSION: MRI-measured TMT is a potential prognostic indicator for MB patients aged 3-12 years, and may help guide risk stratification and treatment planning. To validate its clinical applicability, large-sample prospective researches remain essential.
引用
- An X, Wang J, Yuan J, et al. Prognostic value of temporal muscle thickness in pediatric medulloblastoma patients aged 3-12 years. J Neurooncol. 2025. PMID: 41023500. doi:10.1007/s11060-025-05229-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。